A facile and sensitive HPLC-MS/MS method for quantification of 3,3'-diindolylmethane in plasma samples.

Indole-3-carbinol is the subject of ongoing biomedical research owing to its potential antiatherogenic, anticarcinogenic and antioxidant effects. The antitumor properties are mainly associated with its major metabolite, i.e.

Breast cancer organoid model allowed to reveal potentially beneficial combinations of 3,3'-diindolylmethane and chemotherapy drugs.

Epigenetic alterations represent promising therapeutic targets in cancer treatment. Recently it was revealed that small molecules have the potential to act as microRNA silencers. Capacity to bind the discrete stem-looped structure of pre-miR-21 and prevent its maturation opens opportunities to utilize such compounds for the prevention of initiation, progression, and chemoresistance of cancer.

The role of abnormal hypermethylation of the and promoters in implantation failures in IVF programs.

The objective of this study is to investigate the association between methylation levels of and promoters, clinical parameters, and implantation outcomes after fertilization-embryo transfer (IVT-ET) cycles in women with repeated implantation failures and tubal infertility. Endometrium samples were collected from 34 women during implantation window before IVF-ET cycle to assess methylation status of and promoters using bisulfite sequencing. All participants had a tubal factor of infertility and at least two implantation failures in the anamnesis.

A new promising way of maintenance therapy in advanced ovarian cancer: a comparative clinical study.

Background: There is an urgent need for more novel and efficacious therapeutic agents and strategies for the treatment of ovarian cancer - one of the most formidable female malignancies. These approaches should be based on comprehensive understanding of the pathobiology of this cancer and focused on decreasing its recurrence and metastasis. The aim of this study was to evaluate the efficacy of five-year maintenance therapy with indole-3-carbinol (I3C) as well as I3C and epigallocatechin-3-gallate (EGCG) conducted before, during, and after combined treatment compared with combined treatment alone in advanced ovarian cancer.